Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Drug
Bone health
Online since 8 November 2021, updated 1139 days ago

About this trial

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has...

Included participants

Gender
All
Age
18 - 50 years
Injury level
C4 - T10
  • Severity (AIS)?
  • AIS-A
    AIS-B
    Time since injury
    ≥ 3 years
  • Injury type
  • Traumatic

    Healthy volunteers
    No
    C4-T10

    What’s involved

    Type

    Drug

    Details

    There are no details yet

    Potential benefits

    Main benefits

    Bone health

    Additional benefits

    General health

    Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

    Wings for Life supports SCITrialsFinder

    Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

    Learn more

    • Trial recruitment status
    • Active
    • Trial start date
    • 1 Mar 2021
    • Organisation
    • VA Office of Research and Development
    • Trial recruitment status
    • Active
    • Trial start date
    • 1 Mar 2021
    • Organisation
    • VA Office of Research and Development

    Wings for Life supports SCITrialsFinder

    Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

    Learn more